STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (STORM)
A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial
Sponsor: Charite University, Berlin, Germany
A PHASE2 clinical study on Diffuse Large B-Cell Lymphoma, this trial is ongoing. The trial is conducted by Charite University, Berlin, Germany and has accumulated 9 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Unknown Status PHASE2
▶ Show 4 earlier versions
-
Nov 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Charite University, Berlin, Germany
- Johann Wolfgang Goethe University Hospital
- Johannes Gutenberg University Mainz
- Ludwig-Maximilians - University of Munich
- Mathias Witzens-Harig
- Technical University of Munich
- University Hospital Erlangen
- University Hospital Freiburg
- University Hospital Ulm
For direct contact, visit the study record on ClinicalTrials.gov .